Loading...

Jeffrey Wolf, MD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentMedicine
Address400 Parnassus Avenue
San Francisco CA 94117
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Clinical Trials
    Collapse Global Health

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG, Wolf J, Mitsiades CS, Anderson DJ, Rolfe M. The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of Multiple Myeloma. Mol Cancer Ther. 2017 Sep 06. PMID: 28878026.
      View in: PubMed
    2. Le TX, Wolf J, Peralta CA, Webber AB. Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports. Am J Kidney Dis. 2017 Jun; 69(6):858-862. PMID: 28320553.
      View in: PubMed
    3. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf J, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 Dec 01; 126(12):4640-4653. PMID: 27841764.
      View in: PubMed
    4. Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf J, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 Sep 1. PMID: 27587788.
      View in: PubMed
    5. Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf J. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. Am J Hematol. 2016 Jun; 91(4):400-5. PMID: 26800393.
      View in: PubMed
    6. Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf J, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May 26; 127(21):2561-8. PMID: 26932802.
      View in: PubMed
    7. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KM, Sayre PH, Wolf J, Logan AC. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Jun; 22(6):1030-1036. PMID: 26899561.
      View in: PubMed
    8. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf J, Andreadis C. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 Jul; 57(7):1560-6. PMID: 26490487.
      View in: PubMed
    9. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf J, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83. PMID: 25776193.
      View in: PubMed
    10. Sherbenou DW, Behrens CR, Su Y, Wolf J, Martin TG, Liu B. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015 Mar; 29(2):81-91. PMID: 25294123; PMCID: PMC4482758.
    11. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf J, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44. PMID: 24894413.
      View in: PubMed
    12. Wolf J, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Sep; 53(9):1820-3. PMID: 22288662.
      View in: PubMed
    13. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf J, Albitar M, Berman D, Messina M, Anderson KC. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol. 2010 Aug; 150(4):428-37. PMID: 20618338; PMCID: PMC3418598.
    14. Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf J, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010 Jul; 24(7):1350-6. PMID: 20508619; PMCID: PMC2957585.
    15. Kavanagh JJ, Levenback CF, Ramirez PT, Wolf J, Moore CL, Jones MR, Meng L, Brown GL, Bast RC. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol. 2010 Mar 11; 3:9. PMID: 20222977; PMCID: PMC2851575.
    16. Layzer R, Wolf J. Myeloma-associated polyneuropathy responding to lenalidomide. Neurology. 2009 Sep 08; 73(10):812-3. PMID: 19738177.
      View in: PubMed
    17. Jagannath S, Durie BG, Wolf J, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A, Crowley J, Vescio R. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol. 2009 Sep; 146(6):619-26. PMID: 19622094.
      View in: PubMed
    18. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005 Jun; 129(6):776-83. PMID: 15953004.
      View in: PubMed
    19. Linker CA, Damon LE, Ries CA, Navarro WA, Case D, Wolf J. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant. 2002 Feb; 29(4):297-301. PMID: 11896426.
      View in: PubMed
    20. Govberg IJ, Wolf J, Cotter PD. Trisomy 4 and double minutes in acute myeloid leukemia: further evidence that double minutes can occur as the primary cytogenetic abnormality. Cancer Genet Cytogenet. 2000 Sep; 121(2):212-5. PMID: 11063811.
      View in: PubMed
    21. Damon LE, Wolf J, Rugo HS, Gold E, Zander AR, Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, Linker CA. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant. 2000 Aug; 26(3):257-68. PMID: 10967563.
      View in: PubMed
    22. McGhee EM, Cohen NR, Wolf J, Ledesma CT, Cotter PD. Monosomy 16 as the sole abnormality in myeloid malignancies. Cancer Genet Cytogenet. 2000 Apr 15; 118(2):163-6. PMID: 10748300.
      View in: PubMed
    23. Damon LE, Hu WW, Stockerl-Goldstein KE, Blume KG, Wolf J, Gold E, Cecchi GR, Irwin D, Glaspy J, Territo I, Miller W, Mason JR, Linker CA. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. Biol Blood Marrow Transplant. 2000; 6(5):496-505. PMID: 11063378.
      View in: PubMed
    24. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf J. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant. 1998 Nov; 22(9):865-72. PMID: 9827814.
      View in: PubMed
    25. Lienert-Weidenbach K, Valiante NM, Brown C, White C, Johnston-Dow L, McGinnis M, Krausa P, Lakes DM, Wolf J, Blume KG, Parham P. Mismatches for two major and one minor histocompatibility antigen correlate with a patient's rejection of a bone marrow graft from a serologically HLA-identical sibling. Biol Blood Marrow Transplant. 1997 Nov; 3(5):255-60. PMID: 9450920.
      View in: PubMed
    26. Rugo HS, Damon LE, Ries CA, Wolf J, Linker CA. High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma. Prog Clin Biol Res. 1994; 389:505-11. PMID: 7535460.
      View in: PubMed
    27. Linker CA, Damon LE, Ries CA, Rugo HS, Wolf J. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update. Semin Oncol. 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PMID: 8342075.
      View in: PubMed
    28. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf J. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993 Jan 15; 81(2):311-8. PMID: 8422457.
      View in: PubMed
    29. Wolf J. Why antigens are attracted to the dome epithelium: another clue. Gastroenterology. 1988 Nov; 95(5):1419-21. PMID: 3169506.
      View in: PubMed
    30. Rybicki AC, Heath R, Wolf J, Lubin B, Schwartz RS. Deficiency of protein 4.2 in erythrocytes from a patient with a Coombs negative hemolytic anemia. Evidence for a role of protein 4.2 in stabilizing ankyrin on the membrane. J Clin Invest. 1988 Mar; 81(3):893-901. PMID: 2963832; PMCID: PMC442542.
    31. Spruce WE, Forman SJ, Krance RA, Farbstein MJ, Wolf J, Scott EP, Nademanee AP, Fahey JL, Henke M, Blume KG. Outcome of bone marrow transplantation in patients with extramedullary involvement of acute leukemia. Blut. 1984 Feb; 48(2):75-9. PMID: 6365207.
      View in: PubMed
    32. Forman SJ, Spruce WE, Farbstein MJ, Wolf J, Scott EP, Nademanee AP, Fahey JL, Hecht T, Zaia JA, Krance RA, Findley DO, Blume KG. Bone marrow ablation followed by allogeneic marrow grafting during first complete remission of acute nonlymphocytic leukemia. Blood. 1983 Mar; 61(3):439-42. PMID: 6337652.
      View in: PubMed
    33. Spruce WE, Forman SJ, Blume KG, Farbstein MJ, Scott EP, Wolf J, Krance R. Successful second bone marrow transplantation in a patient with myositis ossificans progressiva and aplastic anemia. Am J Pediatr Hematol Oncol. 1983; 5(4):337-40. PMID: 6367519.
      View in: PubMed
    34. McCutchan JA, Wolf J, Ziegler EJ, Braude AI. Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infections in patients with prolonged neutropenia. Schweiz Med Wochenschr Suppl. 1983; 14:40-5. PMID: 6361990.
      View in: PubMed
    35. Hecht T, Wolf J, Mraz L, Scott EP, Patz LD. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection. JAMA. 1982 Nov 12; 248(18):2301-3. PMID: 6752444.
      View in: PubMed
    36. Wolf J, Spruce WE, Bearman RM, Forman SJ, Scott EP, Fahey JL, Farbstein MJ, Rappaport H, Blume KG. Reversal of acute ("malignant") myelosclerosis by allogeneic bone marrow transplantation. Blood. 1982 Jan; 59(1):191-3. PMID: 7032626.
      View in: PubMed
    37. Forman, S.J., Farbstein, M.J., Scott, E.P., Wolf, J.L., Spruce, W.E., Fahey, J.L., Nademanee, A. and Blume, K.G. N. Engl. J. Med. Prevention and therapy for graft-vs-host disease. 1982; 307:376-377.
    38. Blume, K.G., Forman, S.J., Spruce, W.E., Wolf, J.L., Farbstein, M.J., Scott, E.P., Fahey, J.L., Hecht, T., Findley, D.O., Hill, L.R., Paladugu, R.R., Petz, L.D. and Zaia, J.A. Experimental Hematology Today. Bone marrow transplantation for acute leukemia. 1982; 143-146.
    39. Wolf J, Cukor G, Blacklow NR, Dambrauskas R, Trier JS. Susceptibility of mice to rotavirus infection: effects of age and administration of corticosteroids. Infect Immun. 1981 Aug; 33(2):565-74. PMID: 6268547; PMCID: PMC350737.
    40. Blume KG, Spruce WE, Forman SJ, Wolf J, Farbstein MJ, Scott EP, Fahey JL. Bone-marrow transplantation for acute leukemia. N Engl J Med. 1981 Jul 09; 305(2):101-3. PMID: 7017404.
      View in: PubMed
    41. Wolf J, Rubin DH, Finberg R, Kauffman RS, Sharpe AH, Trier JS, Fields BN. Intestinal M cells: a pathway for entry of reovirus into the host. Science. 1981 Apr 24; 212(4493):471-2. PMID: 6259737.
      View in: PubMed
    42. Blume KG, Spruce WE, Forman SJ, Bross KJ, Beutler E, Farbstein MJ, Fahey JL, Schmidt GM, Scott EP, Wolf J. Bone marrow ablation and marrow transplantation in acute leukemia: influence of clinical pretransplant condition. Transplant Proc. 1981 Mar; 13(1 Pt 1):252-3. PMID: 6267750.
      View in: PubMed
    43. Chillar RK, Wolf J, Bearman RM, Teplitz RL. Terminal deoxynucleotidyl transferase-positive lymphadenopathy in acute-phase chronic granulocytic leukemia. Am J Clin Pathol. 1981 Mar; 75(3):403-6. PMID: 6938125.
      View in: PubMed
    44. Linker CA, Newcom SR, Nilsson CM, Wolf J, Shuman MA. Combined idiopathic neutropenia and thrombocytopenia: evidence for an immune basis for the syndrome. Ann Intern Med. 1980 Nov; 93(5):704-7. PMID: 7212480.
      View in: PubMed
    45. Blume KG, Beutler E, Bross KJ, Chillar RK, Ellington OB, Fahey JL, Farbstein MJ, Forman SJ, Schmidt GM, Scott EP, Spruce WE, Turner MA, Wolf J. Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med. 1980 May 08; 302(19):1041-6. PMID: 6245359.
      View in: PubMed
    46. Wolf J, Perkins HA, Schreeder MT, Vincenti F. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med. 1979 Sep; 91(3):412-3. PMID: 382937.
      View in: PubMed
    47. Wolf J, Mason RG, Honig GR. Regulation of hemoglobin beta-chain synthesis in bone marrow erythroid cells by alpha chains. Proc Natl Acad Sci U S A. 1973 Dec; 70(12):3405-9. PMID: 4519634; PMCID: PMC427246.
    Jeffrey's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP